植物新藥研發-植物新藥

Diabetes is one of the fastest growing diseases in the United States. It is estimated that half of the Americans will be diagnosed with diabetes by 2030 and around ten percent will develop ulcers. Diabetic ulcers are full thickness wounds and even with life threatening risk due to there is no perception, no blood circulation, and easy to get infected. In recent years, European and American scientists use growth factor (PDGF) to treat wounds. Not only is the wound healing slow but the carcinogenic risk is high.

CSTC1 diabetic wound healing new drug, allows faster healing of diabetic wounds and is with non-carcinogenic risk.

The US FDA already approved CSTC1 Phase II clinical trial application in July 2013. According to statistics, the success rate of drug development is only 0.05% while most of the failure are in the clinical trial stage. By treating grade 4 diabetic wound with CSTC1, the ratio of wound healing can be up to 90% in 8 weeks. Apparently, CSTC1 is far better than PDGF based diabetic wound drug and the other drug developed by a Taiwanese biotechnology company, of which the wound healing ratio is claimed to be 50% in 12 weeks.

Using CSTC1 for treating deep second degree burns and full-thickness wounds can help the regeneration of cells of full-thickness skin and hair follicles. Regeneration of full-thickness skin cells comprises of capillary cell regeneration, hair follicle regeneration and can be successfully applied to the healing of diabetic wounds.

EH-CSTC1-01 EH-CSTC1-02 EH-CSTC1-03
EH-CSTC1-04

Historical Timeline

  • 2014
    • The Phase 2 study for botanical new drug CSTC1 for Diabetic Foot Ulcers was granted by the Ministry of Economic Affairs.
    • The new drug CSTC1 for Diabetic Foot Ulcer was approved Phase 2 clinical trial by US FDA and Taiwan FDA and was allowed to start enrollment in KMUH, KMSH and KMTH.
    • Charsire CSTC1 diabetic wound healing new drug was approved to enter clinical trials.
  • 2013
    • CSTC1 was approved by FDA to enter phase II clinical trial.
  • 2011
    • Accomplish the program, CSTC1 diabetes wound healing products of patent extracts, granted by Industrial Development Bureau.